Last reviewed · How we verify

NCT06353776

MicroPulse Transscleral Laser Therapy and Its Short-term Impact on Ocular Surface

Completed NA Last updated 9 April 2024
What this trial tests

NA trial testing conjunctival biopsy after micropulse transscleral laser therapy in Conjunctiva in 15 participants. Completed in 31 October 2023.

Timeline
3 May 2023
Primary endpoint
31 October 2023
31 October 2023

Quick facts

Lead sponsorUniversity Tunis El Manar
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date3 May 2023
Primary completion31 October 2023
Estimated completion31 October 2023
Sites1 location across Tunisia

Drugs / interventions tested

Conditions studied

Sponsor

University Tunis El Manar

Who can join

18 and older, any sex, with Conjunctiva or Cornea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MicroPulse transscleral laser therapy (TLT) is proven to be effective in reducing intraocular pressure with minimal complications in either primary or secondary glaucoma. However, its impact on the human ocular surface remains unexplored. This study aims to bridge this gap by examining the clinical and histopathological effects of MicroPulse TLT on the ocular surface.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Tunis El Manar trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06353776.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing